TP53 and chronic kidney disease: GSEA found that the two Cinacalcet treated groups, when compared to their respective untreated CKD control groups, exhibited significant downregulation of the exact same pathways involved in the ATM signaling pathway (WP654), p53 pathway (WP655) and G1 to S cell cycle control (WP348) as shown in Fig 7A.